IQVIA Holdings Inc. filings document a NYSE-listed operating company with common stock under the IQV symbol and a business centered on clinical research services, commercial insights and healthcare intelligence. Form 8-K reports document quarterly and annual operating results, segment disclosures for R&D Solutions and Commercial Solutions, share repurchase authorizations and amendments to the company's credit agreement.
Proxy and governance filings describe annual meeting matters, director elections and appointments, executive compensation, equity incentive plans and stockholder voting items. The filings also provide formal records of capital-structure terms, material agreements and board oversight for IQVIA's life sciences and healthcare services business.
IQVIA Holdings Inc. reported third-quarter 2026 revenue of $4.428 billion, up 8.0% year over year. GAAP net income attributable to IQVIA was $350 million; Adjusted EBITDA was $1.032 billion, up 8.7%, and adjusted diluted EPS was $3.34, up 11.3%. Commercial Solutions revenue was $1.789 billion, up 6.9%; R&D Solutions revenue was $2.639 billion, up 8.7%.
R&D Solutions net new bookings were $3.2 billion, up 15%, and contracted backlog was $32.6 billion as of September 30, 2026; approximately $9.4 billion was expected to convert to revenue in the next twelve months. A review of inactive trials adjusted backlog by approximately $2.1 billion, with no impact on historical financial results, 2026 guidance, book-to-bill or next-twelve-month revenue from backlog estimates. Operating cash flow was $825 million and free cash flow was $667 million, versus $908 million and $772 million, respectively, in Q3 2025. IQVIA raised full-year 2026 guidance to revenue of $17.350 billion to $17.500 billion, Adjusted EBITDA of $4.025 billion to $4.055 billion and adjusted diluted EPS of $12.90 to $13.00. Revenue guidance includes 250 basis points of acquisition contribution, including acquisitions the company expects to complete by year-end, and approximately 20 basis points of foreign-exchange tailwind.
IQVIA Holdings Inc. reported that its wholly owned subsidiary, IQVIA Inc., completed the issuance and sale of notes with $2,000,000,000 in gross proceeds. The unsecured notes bear interest at 6.375% per year and mature on March 15, 2034. Net proceeds will be used to redeem in full the subsidiary’s 5.000% senior notes due 2026, repay a portion of its outstanding revolving credit facility indebtedness, and pay offering fees and expenses.
Interest is payable semi-annually on March 15 and September 15, beginning March 15, 2027. The issuer may redeem the notes before maturity, subject to a customary make-whole premium; before September 15, 2029, the notes are also subject to a customary “equity claw” redemption right. After that date, a redemption premium declines from 3.188% to 0.000%.
IQVIA HOLDINGS INC. (IQV) reported that its wholly owned subsidiary, IQVIA Inc., has priced a private offering of $2,000,000,000 aggregate principal amount of senior notes due March 15, 2034, bearing interest at 6.375% per annum and paying semi-annual interest starting March 15, 2027.
The company plans to use the net proceeds to redeem in full its existing Senior 5.000% Notes due 2026, repay a portion of the outstanding indebtedness under its revolving credit facility, and pay fees and expenses related to the notes offering. The issuance of the notes is expected to occur on or about September 23, 2026, subject to customary closing conditions, and is being conducted as a private offering under Rule 144A and Regulation S.
IQVIA HOLDINGS INC. (IQV) executive James G. Berkshire, EVP Global Infrastructure and Operations, reported multiple transactions on September 2, 2026 involving company equity. He exercised stock appreciation rights for 5,381 shares of common stock at an exercise price of $131.82 per share, eliminating this derivative position. On the same date he sold 2,668 shares of common stock at $261.33 per share and disposed of 2,713 shares back to the issuer at $261.54 per share. No transactions are reported as made under a Rule 10b5-1 trading plan.
IQVIA HOLDINGS INC. (IQV) is the issuer for a proposed sale of common stock by James G. Berkshire under Rule 144. The notice lists 2,668 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, associated with stock appreciation rights, with a proposed sale date of September 2, 2026 on the NYSE.
IQVIA HOLDINGS INC. officer W. Richard Staub reported selling 5,500 shares of Common Stock on 2026-08-03 at $232.68 per share in a sale classified as an open market or private transaction. Following this sale, he directly owns 13,312 shares. The filing does not indicate use of a Rule 10b5-1 trading plan.
IQVIA Holdings Inc. officer Patel Bhavik, President, MedTech and Consumer Health, reported selling 1,855 shares of common stock on July 31, 2026. The sale was at a weighted average price of $235.27 per share, with individual trades between $235.22 and $235.29. Following this transaction, Bhavik directly holds 1,348 shares of IQVIA common stock.
A shareholder of IQV (ticker IQV) has filed a notice to sell shares of the company’s common stock under Rule 144. The planned sale totals 5,500 shares of common stock, to be handled through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated aggregate market value of $1,279,740.00. The filing lists blocks of restricted stock and performance shares granted between 2018 and 2021 that make up the shares to be sold, with a proposed sale date of 08/03/2026 on the NYSE.
IQVIA Holdings Inc. executive officer Eric Sherbet reported a sale of 5,000 shares of Common Stock on July 29, 2026 at $249.16 per share in a sale characterized as an open market or private transaction. After this transaction, he directly held 20,999 shares.
IQVIA HOLDINGS INC. reported that officer Keriann Cherofsky sold 558 shares of common stock on July 29, 2026 at $245.21 per share in an open-market or private transaction. After this sale, she directly holds 2,989 shares. The trade was not flagged as under a Rule 10b5-1 plan.